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Abstract: Sucroferric oxyhydroxide (VELPHORO®) is a polynuclear iron-based phosphate binder recently approved for the treatment of 
hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the 
optimal combination of good efficacy, adequate tolerability and low pill burden, sucroferric oxyhydroxide constitutes a promising 
alternative. Among the attributes of an ideal phosphate binder is minimal absorption and, hence, low risk of systemic toxicity. 
Accordingly, the iron-releasing properties and absorption, distribution, metabolism and excretion (ADME) profile of sucroferric 
oxyhydroxide, as well as the possibility of iron accumulation and toxicity, were investigated in a series of preclinical studies. The effect 
of sucroferric oxyhydroxide on the progression of vascular calcification was also investigated. Sucroferric oxyhydroxide exhibited a high 
phosphate-binding capacity and low iron-releasing properties across the physiological pH range found in the gastrointestinal tract. In the 
ADME studies, uptake of 59Fe-radiolabelled sucroferric oxyhydroxide was low in rats and dogs (<1% from a 50 mg Fe/kg bodyweight 
dose), with the majority of absorbed iron located in red blood cells. Long-term (up to 2 years) administration of sucroferric oxyhydroxide 
in rats and dogs was associated with modest increases in tissue iron levels and no iron toxicity. Moreoever, in uraemic rats, sucroferric 
oxyhydroxide was associated with reduced progression of vascular calcification compared with calcium carbonate. In conclusion, 
sucroferric oxyhydroxide offers a new option for the treatment of hyperphosphataemia, with a high phosphate-binding capacity, minimal 
iron release, and low potential for iron accumulation and toxicity. 
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INTRODUCTION 
 Chronic kidney disease (CKD) is defined as prolonged damage 
of the kidney lasting more than 3 months, featuring structural or 
functional abnormalities and characterised by a reduced glomerular 
filtration rate (GFR), increased urinary albumin excretion, or a 
combination of the two [1-3]. A growing international public health 
concern, CKD has an estimated worldwide prevalence of 8–16% 
with a 5-year survival rate of just 46% for patients aged around 60 
years [1, 4]. The Kidney Disease Outcomes Quality Initiative 
(K/DOQI) has identified five stages of CKD according to the 
remaining level of kidney function, defined in terms of the GFR [2]. 
Patients in the latter stage of CKD (Stage 5) may experience kidney 
failure (end-stage renal disease, ESRD), requiring treatment with 
dialysis or transplantation [5]. 
 The decline of kidney function in CKD is associated with a 
progressive decline in the homeostasis of various minerals and the 
disruption of bone metabolism, collectively known as CKD-mineral 
bone disorder (CKD-MBD) [6, 7]. Phosphorus homeostasis plays a 
key role in CKD-MBD [8]. In people with Stage 4 or Stage 5 CKD, 
the rate of phosphorus excretion declines until the rate of dietary 
intake exceeds excretion, leading to hyperphosphataemia [9]. 
Hyperphosphataemia occurs in almost all patients undergoing 
dialysis, despite dietary restriction of phosphate, and may begin in 
CKD Stage 3 [6, 9]. 
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 The disturbances of mineral homeostasis found in CKD-MBD 
have been associated with a risk of mortality [10, 11]. In a 
systematic review of 35 studies, Covic et al. found a significant 
relationship between mineral parameters and all-cause mortality, 
cardiovascular mortality and cardiovascular events in patients with 
CKD [11]. Of the three mineral metabolism parameters investigated 
(phosphorus, calcium and parathyroid hormone [PTH]), phosphorus 
was associated with the greatest risk of death; of the 35 studies 
included in the review, 17 assessed the all-cause mortality risk 
associated with high serum phosphorus and all but one 
demonstrated a significant relationship, compared with six of nine 
studies for calcium and seven of eleven studies for PTH. An earlier 
retrospective study of 40,538 haemodialysis patients in the United 
States of America (USA) also found step-wise increases in the 
relative risk (RR) of death and the risk of cardiovascular 
hospitalisation with increases of serum phosphorus concentrations 
above 5.0 mg/dL [12]. RR of death also showed a step-wise 
increase with increases in serum calcium within four strata of serum 
phosphorus concentrations (calcium concentrations were investigated 
with respect to serum phosphorus concentrations due to the 
tendency of the serum concentrations of each mineral to rise as the 
other falls, and vice versa). It is notable, however, that even within 
the normal range (2.5–4.5 mg/dL), increases in serum phosphorus 
concentrations may be associated with a significantly increased risk 
of death [6, 13]. 
 Beyond the increased risk of all-cause mortality, 
hyperphosphataemia is specifically associated with increased risk of 
cardiovascular morbidity and mortality [14, 15]. In the United 
States Renal Data System (USRDS) study of 14,829 haemodialysis 
 1875-5453/14 $58.00+.00 © 2014 Bentham Science Publishers
954    Current Drug Metabolism, 2014, Vol. 15, No. 10 Cozzolino et al. 
patients, step-wise relationships were found between serum 
phosphorus concentrations above 4.5 mg/dL and risk of 
cardiovascular events, and between serum phosphorus concentrations 
above 6.4 mg/dL and risk of death [15]. A systematic review and 
meta-analysis of 47 cohort studies, meanwhile, found a 35% 
increase in the risk of death for every 1 mg/dL increase in serum 
phosphorus in three adequately-adjusted studies, with an 18% 
increase in the risk of death for every 1 mg/dL increase in serum 
phosphorus in the 13 available studies overall [14]. 
 The strong relationship between hyperphosphataemia and 
cardiovascular morbidity and mortality indicates that increased 
serum phosphorus has a specific deleterious effect on the 
cardiovascular system, thought to result from accelerated 
calcification of the vasculature [16]. In vitro studies of human aortic 
smooth muscle cell cultures have shown that, in the presence of 
inorganic phosphate at hyperphosphataemic levels (>4.33 mg/dL), 
the expression of osteoblastic differentiation markers is heightened 
and calcification increases in a concentration-dependent manner, 
suggesting that elevated serum phosphorus may predispose vascular 
smooth muscle cells to calcification [17]. A study of rat aortic 
smooth muscle cells, meanwhile, found increased calcification in 
the presence of inorganic phosphate, which was enhanced by the 
addition of ascorbic acid [18]. The same study also found that the 
expression of markers of osteoblastic differentiation was increased 
in the presence of inorganic phosphate plus ascorbic acid. The 
enhancing effect of hyperphosphataemia on vascular calcifications 
has also been demonstrated in clinical studies. For example, the 
Multi-Ethnic Study of Atherosclerosis found a graded relationship 
between serum phosphorus concentrations and vascular 
calcification of the descending thoracic aorta, aortic valve and 
mitral valve in 439 patients with moderate CKD and no clinical 
cardiovascular disease at baseline [19]. Furthermore, it was found 
that even moderate increases in serum phosphorus levels in people 
with CKD may lead to cardiovascular calcification.  
 Given the strength of the association between hyperphosphataemia 
in CKD and vascular calcification, cardiovascular morbidity and 
mortality, and all-cause mortality, it is to be expected that 
correcting the phosphorus balance is an important part of the 
therapeutic strategy for CKD [6]. Restricting dietary phosphorus 
intake is difficult to maintain and insufficient to normalise serum 
phosphorus concentrations in the majority of patients [4, 20, 21]. 
Standard intermittent haemodialysis performed three times weekly 
is also usually unable to maintain serum phosphate at appropriate 
levels, necessitating the use of phosphate binder therapy in patients 
with CKD [22]. Phosphate binders block the intestinal absorption of 
phosphate by forming an insoluble complex with it or by binding it 
into a resin [4, 20]. Research has confirmed that treatment with 
phosphate binders reduces mortality in CKD patients on dialysis 
[20]. Phosphate binders should be effective and well tolerated, with 
a high efficiency across a wide pH range (such as is found in the 
gastrointestinal [GI] tract) [9, 23]. To be considered ideal, however, 
a phosphate binder should also be palatable and inexpensive, with 
minimal potential for systemic absorption from the digestive tract 
and a sufficiently low pill burden to help ensure adherence to 
treatment [9, 23, 24]. 
 Available phosphate binders include aluminium-, calcium- and 
magnesium-based binders, in addition to sevelamer and lanthanum 
carbonate [4, 25]. Each of these is associated with considerable 
disadvantages. Aluminium salts are highly effective but may be 
associated with toxicity, having been linked to encephalopathy and 
anaemia [26, 27]. Calcium acetate and calcium carbonate are 
effective and inexpensive but may increase hypercalcaemia, and 
have been associated with the progression of vascular calcification 
[27-30]. Sevelamer and lanthanum, meanwhile, are expensive and 
may be associated with GI side effects [4, 31]. In addition, 
sevelamer is associated with a high pill burden and there are 
concerns surrounding the potential for accumulation of lanthanum 
from lanthanum carbonate, although these have been reduced  
to some extent by more recent long-term data [9, 32-34]. 
Consequently, it may be concluded that an ideal phosphate binder 
combining the optimal set of characteristics listed above is not yet 
available on the market. 
 Sucroferric oxyhydroxide (VELPHORO
®
) is a novel, iron-
based phosphate binder, which could provide an alternative to the 
existing phosphate binder treatment options [35, 36]. It is a 
polynuclear iron(III)-oxyhydroxide (pn-FeOOH) based compound 
in which the addition of sucrose prevents iron(III)-oxyhydroxide 
from ageing, thereby maintaining its phosphate binding capacity 
[35]. Sucroferric oxyhydroxide contains ~ 33% (m/m) of the active 
moiety pn-FeOOH (corresponding to an iron content of ~ 21% 
[m/m]), ~ 30% (m/m) sucrose, ~ 28% (m/m) starches and 10% 
(m/m) water [37]. Iron is an essential trace element, but in its free 
form it is toxic due to its ability to generate reactive oxygen species, 
which can damage biological macromolecules such as DNA [38-
40]. The nature of iron toxicity and the possibility of intestinal iron 
absorption are, therefore, important considerations when assessing 
the therapeutic potential of an iron-based phosphate binder such as 
sucroferric oxyhydroxide. 
 In order to balance the simultaneous requirement for iron and 
its potential toxicity, in biological systems iron is bound with 
ligands, such as proteins or other prosthetic groups, which reduce 
its reactivity and attenuate its potential to cause harm [38, 41]. In 
humans, iron is stored in ferritin, which consists of an iron (III)-
oxyhydroxide core stabilised by a protein shell, and it is transported 
in transferrin, a glycoprotein consisting of a single polypeptide 
chain with two iron-binding sites [41, 42]. Iron is mainly stored in 
the liver and spleen in hepatocytes and macrophages, but the 
maintenance of iron levels is regulated by absorption in the small 
intestine [38, 43]. Absorption of iron from the diet is low – 
typically between 1–2 mg/day of a dietary intake of 12–18 mg/day 
– but excessive dietary intake can cause iron overload and toxicity 
[38, 43, 44]. In the iron-overloaded state, liver levels of ferritin and 
haemosiderin (another iron storage molecule, of which denatured 
ferritin subunits are a major constituent) may be markedly increased 
[45, 46]. Haemosiderin has been implicated in tissue damage in the 
iron-overloaded state [47], and the liver is the organ most likely to 
be affected by iron overload [48]. Non-transferrin-bound iron 
(NTBI), which corresponds to iron that is unbound to either 
transferrin, ferritin or haem (the other major protein associated with 
iron), also plays a major role in iron overload [41]. When the serum 
transferrin iron capacity is saturated, the majority of any additional 
iron absorbed from the intestine is deposited in the liver, with  
58–75% of NTBI removed from the serum by the liver in a single 
pass [41]. The capacity of the liver to excrete NTBI into bile may 
also be reduced under iron-loaded conditions [49]. Although the 
pathological significance of NTBI is unclear, there is growing 
evidence pointing towards a damaging effect [41]. For example, 
NTBI has been linked with heart disease and liver damage in 
patients with thalassaemia [50]. 
 In order to be considered ‘ideal’, therefore, an iron-based 
phosphate binder would need to combine high phosphate-binding 
capacity with minimal systemic absorption of iron and low potential 
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for iron-related side effects, including those that may be associated 
with the release of iron in the GI tract. The iron(III)-oxyhydroxide 
component of sucroferric oxyhydroxide was designed to be 
practically insoluble, with the intention of minimising intestinal 
absorption [51]. Nevertheless, the avoidance of iron accumulation 
in the body must be demonstrated for an iron-based phosphate 
binder if it is to be considered safe, particularly given the likelihood 
of long-term use. 
 This review summarises the results of several preclinical in 
vitro and animal studies that evaluated the pharmacological 
properties of sucroferric oxyhydroxide, including its phosphate-
binding capacity, iron release and systemic absorption, and 
potential long-term effects on iron status and progression of 
vascular calcification. 
PRECLINICAL DATA REVIEW 
 The phosphate binding and iron-releasing properties of 
sucroferric oxyhydroxide were assessed in vitro under conditions 
simulating administration on both an empty stomach and a full 
stomach, across the typical pH range that sucroferric oxyhydroxide 
would be exposed to during passage through the GI tract [37]. Iron 
absorption, distribution, metabolism and excretion (ADME), 
meanwhile, were assessed in vivo in rats and dogs administered 
59
Fe-labelled sucroferric oxyhydroxide. Several toxicological 
studies (ranging from 4 weeks to 2 years) also examined the potential 
effects of sucroferric oxyhydroxide on iron stores and iron-related 
toxicity in rats and dogs. Finally, the efficacy of sucroferric 
oxyhydroxide in preventing vascular calcifications was assessed in 
a uraemic rat model with adenine-diet-induced CKD [52]. 
Phosphate Binding and Iron-Releasing Properties of 
Sucroferric Oxyhydroxide In Vitro 
 To evaluate the expected phosphate-binding and iron-releasing 
properties of sucroferric oxyhydroxide when administered to human 
patients, a series of five experiments were conducted in vitro to 
assess these properties under physiologically relevant conditions – 
that is, across the pH range that would be encountered in the GI 
tract [37]. The first two experiments examined the phosphate-
binding capacity of sucroferric oxyhydroxide under conditions 
simulating its administration on an empty stomach (i.e., with an 
excess of sucroferric oxyhydroxide over phosphate) and on a full 
stomach. In the first experiment, the pH was increased at five pre-
determined time points, from a starting pH of 1.2 to a final pH of 
7.5, with the experiment lasting 8 hours in total. In the second 
experiment, the pH was raised or lowered at five pre-determined 
time points over the course of 28 hours to simulate the 
physiological conditions that would be encountered during the 
passage of sucroferric oxyhydroxide through the GI tract. The iron-
releasing properties of sucroferric oxyhydroxide were then 
investigated in a second set of three experiments designed to 
simulate administration on: 1) an empty stomach in the absence of 
phosphate; 2) an empty stomach in the presence of phosphate; and 
3) a full stomach (in the presence of phosphate) across the pH range 
that sucroferric oxyhydroxide would be exposed to in the GI tract. 
 In the first set of experiments, sucroferric oxyhydroxide showed 
robust phosphate-binding capacity over the entire physiologically-
relevant pH range [37]. Under conditions representative of 
administration on an empty stomach, phosphate adsorption was 
highest at pH 2.5 (0.21 mg P/mg Fe) but only slightly lower at pH 
1.3 (0.18 mg P/mg Fe). Above pH 2.5, phosphate adsorption 
decreased slightly with increasing pH (Fig. 1a). Under conditions 
simulating administration on a full stomach, it took some time for 
chemical equilibrium to be reached; phosphate adsorption was 0.15 
mg P/mg Fe at pH 5.9 after a short, 15-minute exposure, but was 
higher at each time point thereafter, regardless of whether the pH 
was raised or lowered, including at a similar pH of 6.7 after 6 hours 
(0.24 mg P/mg Fe) (Fig. 1b). The maximum bound phosphate to 
iron ratio was found to be 0.26 mg P/mg Fe, recorded at pH 2.6. 
 In the second set of experiments, sucroferric oxyhydroxide 
showed minimal iron release (0.35%) across a pH range of 2.6–8.0 
under conditions simulating being taken on a full stomach (Fig. 2) 
[37]. Although iron release was high (67%) at an initial pH of 1.2 
(final pH 2.1) under conditions simulating administration on an 
empty stomach and in the absence of phosphate (conditions which 
are of a rather theoretical nature), this fell to just 6% under similar 
conditions (initial and final pH 1.2) in the presence of phosphate 
(Table 1). 
 These in vitro experiments show that sucroferric oxyhydroxide 
has a robust phosphate-binding capacity across the full 
physiologically-relevant pH range [37]. This indicates that phosphate 
binding could begin in the stomach and continue throughout the 
length of the GI tract, thus maximising the potential for phosphate 
binding – and minimising the potential for phosphate absorption  
– at any stage during the passage of food through the digestive tract. 
The minimal iron release properties observed may support clinical 
features such as minimal iron absorption and low risk for systemic 
iron accumulation and toxicity. Further investigations were needed 
in vivo, however, before any firm predictions could be made about 
the potential of sucroferric oxyhydroxide to cause iron toxicity and 
accumulation with clinical use. 
Iron Absorption, Distribution, Metabolism and Excretion In 
Vivo in Rats and Dogs Administered 
59
Fe-labelled Sucroferric 
Oxyhydroxide 
 To begin to assess the potential for iron absorption and 
accumulation from sucroferric oxyhydroxide, two preclinical 
ADME studies were conducted in rats and dogs. These new data 
will be discussed here. Both experiments were conducted in 
accordance with the requirements of current, internationally 
recognised Good Laboratory Practice Standards, and the applicable 
sections of the United Kingdom (UK) Animals (Scientific 
Procedures) Act 1986. 
 Iron-replete rats and dogs were administered a 50 mg Fe/kg 
bodyweight dose of 
59
Fe radiolabelled sucroferric oxyhydroxide. 
For both groups of animals, a COBRA II Gamma Counter (Model 
5003; Canberra Packard, Pangbourne, UK) with the capability to 
count low-level activity and higher energy isotopes was used to 
measure radioactivity. In rats, radioactivity was mainly found in the 
red blood cells (RBCs), with 0.62% of the total radioactivity from 
the administered dose found in these cells, corresponding to 78% of 
the total radioactivity retrieved. Some radioactivity was also found 
in the liver, amounting to 0.18% of the total from the administered 
dose and corresponding to 22% of the total amount of radioactivity 
retrieved (Fig. 3). Radioactivity was measured in dogs 7 days after 
administration. Similar to the findings in rats, 0.82% of the total 
radioactivity from the administered dose was found in RBCs, 
corresponding to 85% of the total amount of radioactivity retrieved. 
In one dog, 0.14% of the total radioactivity from the administered 
dose was found in the spleen, corresponding to 15% of the total 
amount of radioactivity retrieved in that animal. No radioactivity 
was found in two dogs. In both rats and dogs, 
59
Fe was excreted 
exclusively in the faeces. 
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1a) 
 
 
1b) 
Fig. (1). Phosphate adsorption under conditions representative of administration on 1a) an empty stomach and 1b) a full stomach during passage through the 
gastrointestinal tract [37]. *Average of duplicate samples. Observed changes in final pH values are due to buffering capacity of sucroferric oxyhydroxide and 
the dissolution process. Reproduced from Wilhelm et al. 2014 with permission from Dustri-Verlag. 
 
 
 
Fig. (2). Iron release from sucroferric oxyhydroxide under conditions representative of administration on a full stomach during passage through the 
gastrointestinal tract [37]. *Average of duplicate samples.  Observed changes in final pH values are due to buffering capacity of sucroferric oxyhydroxide and 
the dissolution process. 
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Table 1. Iron release from sucroferric oxyhydroxide under conditions representative of administration on a) an empty stomach in 
the absence of phosphate; b) an empty stomach in the presence of phosphate; c) a full stomach, in the presence of 
phosphate, during passage through the gastrointestinal tract [37]. Reproduced from Wilhelm et al. 2014 with permission 
from Dustri-Verlag. 
Initial pH of samples Final pH of samples Duration of exposure Iron release (%) SD (%) 
a) Empty stomach: in the absence of phosphate 
1.2 2.1 1 hour 66.90 3.10 
b) Empty stomach: in the presence of phosphate 
1.2 1.2 1 hour 6.24 0.59 
c) Full stomach: passage of sucroferric oxyhydroxide through the GI tract (in the presence of phosphate) 
4.5 5.9 15 minutes 0.31 N/A 
2.5 2.6 2 hours 0.35 N/A 
8.5 8.0 15 minutes 0.26 N/A 
6.5 6.7 3.5 hours 0.28 N/A 
7.0 6.9 22 hours 0.30* N/A 
*Average of duplicate samples. N/A, data not available; SD, standard deviation. 
Observed changes in final pH values due to buffering capacity of sucroferric oxyhydroxide and the dissolution process. 
 
 
Fig. (3). Amount of radiolabelled iron found in red blood cells, liver, spleen and bone marrow in rats after a single dose administration of 59Fe-labelled 
sucroferric oxyhydroxide (50 mg Fe/kg bodyweight). 
 
 The two ADME studies in iron-replete rats and dogs 
demonstrated that iron uptake from sucroferric oxyhydroxide was 
low (1% from a 50 mg Fe/kg dose). In clinical practice, iron 
absorption depends on a number of different factors, including the 
saturation of iron stores and inflammatory status [44, 53-56]. The 
results of these animal studies may, however, suggest a low 
systemic impact of sucroferric oxyhydroxide on iron parameters. It 
is particularly interesting that what little iron was absorbed was 
mainly found in the RBCs. After absorption, iron is bound to 
transferrin and travels either to the liver, for storage in hepatocytes, 
or to RBCs for production of haemoglobin [43]. Thus it would 
appear that the low levels of iron that were absorbed from 
sucroferric oxyhydroxide were used for haemoglobin synthesis – a 
normal part of iron metabolism [43] – even though the test animals 
were iron-replete. If iron absorption from sucroferric oxyhydroxide 
is low, and what iron is absorbed is subject to the normal metabolic 
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processes, then it should follow that sucroferric oxyhydroxide 
carries a low risk of iron toxicity. As CKD is a chronic condition, 
however, phosphate binder use may be required over a long period 
of time. It was, therefore, important to evaluate the potential for 
iron accumulation and toxicity associated with long-term use of 
sucroferric oxyhydroxide. 
Toxicological Studies of the Effect of Sucroferric Oxyhydroxide 
on Iron Stores and Iron-related Toxicity in Rats and Dogs 
 The effect of sucroferric oxyhydroxide on iron accumulation 
and iron-related toxicity was investigated in seven sub-chronic, 
chronic and long-term studies in rats and dogs; new data from these 
studies are presented below. All studies were conducted in 
accordance with the requirements of current, internationally 
recognised Good Laboratory Practice Standards, and the applicable 
sections of the UK Animals (Scientific Procedures) Act 1986. 
 In the four rat studies, sucroferric oxyhydroxide was 
administered orally via the diet at clinically-relevant doses (40 mg 
Fe/kg bodyweight/day) or higher to equal numbers of male and 
female rats for periods of 4, 13 and 26 weeks, and up to 2 years. 
The doses administered in each of the four studies can be seen in 
Table 2. During the studies, the rats’ clinical condition, bodyweight, 
food consumption, ophthalmic condition, haematology, blood 
chemistry, serum vitamin analysis, urinalysis, tissue iron, bone 
turnover, organ weights, macropathology and histopathology were 
investigated. All animals were subject to detailed necropsy after 
sacrifice upon completion of the studies. 
 Dose-related increases in liver iron content were observed in 
treated animals relative to controls in all four rat studies. At 
clinically relevant doses (40 mg Fe/kg/day), however, the liver 
iron values of treated rats were not significantly higher than those 
found in control animals after 2 years of treatment (liver iron 
values were 8% and 16% higher in male and female treated rats 
than control rats, respectively; p0.05) (Table 2). After 26 weeks, 
liver iron values were 21% and 18% higher in male and female 
treated rats, respectively, than in control rats. At higher doses of 
sucroferric oxyhydroxide, liver iron concentrations in treated 
animals tended to stabilise over time. For example, the relative 
increase in liver iron values among treated animals compared with 
controls was similar in the 500 mg Fe/kg/day dose groups for 
each of the 4-week, 26-week and 2-year studies (Table 2). Tissue 
iron values were also recorded after 6 weeks of recovery at the 
end of the 26-week study for the high-dose group (500 mg 
Fe/kg/day) only. Iron values in treated rats continued to be 
elevated relative to controls in the liver and spleen, but did show 
some signs of recovery. 
Table 2. Mean liver tissue iron content in rats after administration of sucroferric oxyhydroxide for 4, 13 and 26 weeks, and 2 
years. 
Liver iron content, group mean values: rat studies Male rats Female rats 
Study 
number 
Study 
duration 
  
Control 
group 
Group 1 
(low 
dose) 
Group 2 
(mid 
dose) 
Group 3 
(high 
dose) 
Control 
group 
Group 
1 
Group 
2 
Group 
3 
Dose (mg Fe/kg bodyweight/day) - 100 200 500 - 100 200 500 
1 4 weeks Iron concentration in mg/kg 
(relative value compared with 
control) 
110 
151* 
(x1.37) 
167* 
(x1.52) 
275* 
(x2.50) 
306 
455* 
(x1.49) 
426* 
(x1.39) 
581* 
(x1.90) 
Dose (mg Fe/kg bodyweight/day) - 60 200 600 - 60 200 600 
2 13 weeks Iron concentration in mg/kg 
(relative value compared with 
control) 
192 
227* 
(x1.18) 
242* 
(x1.26) 
531* 
(x2.77) 
423 
523 
(x1.24) 
597* 
(x1.41) 
926* 
(x2.19) 
Dose (mg Fe/kg bodyweight/day) - 40 150 500 - 40 150 500 
174 
210* 
(x1.21) 
268* 
(x1.54) 
477* 
(x2.74) 
438 
515* 
(x1.18) 
610* 
(x1.39) 
781* 
(x1.78) 3 26 weeks Iron concentration in mg/kg 
(relative value compared with 
control)† 182     
415* 
(x2.28) 
429     
565 
(x1.32) 
Dose (mg Fe/kg bodyweight/day) - 40 150 500 - 40 150 500 
4 2 years Iron concentration in mg/kg 
(relative value compared with 
control) 
322 
348 
(x1.08) 
423* 
(x1.31) 
780* 
(x2.42) 
427 
495 
(x1.16) 
786* 
(x1.84) 
1315* 
(x3.08) 
* Significant when compared with untreated control group (p<0.05). 
† Second row shows mean liver tissue iron content after 6 weeks of recovery. 
Non-clinical Characteristics of Sucroferric Oxyhydroxide Current Drug Metabolism, 2014, Vol. 15, No. 10    959 
 Overall, there were no notable differences in kidney iron values 
between treated and control rats in any of the studies; small but 
significant increases (p<0.01) in kidney iron values were mainly 
confined to female rats at higher doses. In all four studies, the iron 
content of the spleen varied greatly between rats. After 2 years, 
spleen iron values did not differ significantly between rats 
administered clinically-relevant doses (40 mg Fe/kg/day) and 
controls (p0.05). There were a few cases of significant spleen iron 
value increases (p<0.01) in treated rats compared with controls in 
each study, but these did not appear to be dose-dependent. 
 In the three controlled dog studies, sucroferric oxyhydroxide 
was administered twice daily by oral capsule at clinically-relevant 
doses (40 mg Fe/kg/day) or higher to equal numbers of male and 
female dogs for periods of 4, 13 and 26–39 weeks. Doses 
administered in each of the three studies can be seen in Table 3. In 
addition to the investigational assessments undertaken in rats, 
electrocardiography and blood pressure were also assessed. As in 
the rat studies, all animals were subject to detailed necropsy after 
sacrifice upon the studies’ completion. 
 In the dog studies, tissue iron levels varied greatly between 
dogs after 4, 13 and 39 weeks. Findings with respect to liver iron 
levels did, however, complement those from the rat studies (Table 3). 
Liver iron values increased in treated animals compared with 
controls in each of the studies, although these increases did not 
appear to be dose-dependent. After 39 weeks of treatment, liver 
iron values were not more than 40% higher among dogs treated 
with clinically-relevant doses (40 mg Fe/kg/day) than controls for 
either sex, and did not reach statistical significance (p0.05). Even 
at the highest dose of sucroferric oxyhydroxide (400 mg Fe/kg/day, 
around ten times higher than a human dose), liver iron values were 
less than 2.5 times greater in treated dogs than in controls after 39 
weeks of treatment. Overall, there was no notable effect of 
treatment on kidney or spleen iron levels at clinically-relevant doses 
(40 mg Fe/kg/day) in any of the studies. At the highest dosage in 
the 39-week study (400 mg Fe/kg/day), increased tissue iron values 
compared with controls persisted after 6 weeks of recovery. 
 Histopathological analyses in both the rat and dog studies 
revealed iron to be found mainly in the reticuloendothelial system 
(RES). In the 2-year rat study, the degree of macrophage 
pigmentation (defined as minimal, slight or moderate) increased in 
a dose-dependent manner, but the macrophage staining was only 
observed in a statistically significant number of animals at doses of 
150 and 500 mg Fe/kg/day (p<0.01). The number of rats with 
pigmented hepatocytes, meanwhile, did not reach statistical 
significance at any treatment dose. In the 39-week dog study, 
moderate positive staining of Kupffer cells/macrophages was 
observed in liver sections from dogs administered 120 mg Fe/kg/day 
(males only) and 400 mg Fe/kg/day (males and females) stained 
with Perls’ Prussian blue. Positive Perls’ staining of hepatocytes, 
meanwhile, was only observed in female dogs administered doses 
of 120 or 400 mg Fe/kg/day and was minimal.  
 Elevated haematocrit and haemoglobin concentrations were 
observed in the highest dose groups (500 mg Fe/kg/day) for male 
rats in the 2-year study, and for male and female rats in the 26-week 
study. These appeared to recover during the 6-week recovery period 
following the 26-week study. In the dog studies, there were no 
notable haematological differences in treated dogs compared with 
control dogs. 
 Together, the toxicity studies undertaken in rats and dogs show 
that iron accumulation resulting from administration of sucroferric 
Table 3. Mean liver tissue iron content in dogs after administration of sucroferric oxyhydroxide for 4, 13, 26 and 39 weeks. 
Liver iron content, group mean values: dog studies Male dogs Female dogs 
Study 
number 
Study 
duration 
  
Control 
group 
Group 1 
(low 
dose) 
Group 2 
(mid 
dose) 
Group 3 
(high 
dose) 
Control 
group 
Group 
1 
Group 
2 
Group 
3 
Dose (mg Fe/kg bodyweight/day) - 100 200 400 - 100 200 400 
1 4 weeks Iron concentration in mg/kg 
(relative value compared with 
control) 
393.3 
373.3 
(x0.95) 
386.7 
(x0.98) 
420 
(x1.07) 
296.7 
300 
(x1.01) 
406.7 
(x1.37) 
380 
(x1.28) 
Dose (mg Fe/kg bodyweight/day) - 100 200 400 - 100 200 400 
2 
13 
weeks 
Iron concentration in mg/kg 
(relative value compared with 
control) 
423 
725* 
(x1.71) 
595* 
(x1.41) 
570* 
(x1.35) 
308 
445 
(x1.44) 
580 
(x1.88) 
420 
(x1.36) 
Dose (mg Fe/kg bodyweight/day) - 40 120 400 - 40 120 400 
3 
26 
weeks 
Iron concentration in mg/kg 
(relative value compared with 
control) 
390 - 
703 
(x1.80) 
563 
(x1.44) 
370 - 
480 
(x1.30) 
683 
(x1.85) 
Dose (mg Fe/kg bodyweight/day) - 40 120 400 - 40 120 400 
4 
39 
weeks† 
Iron concentration in mg/kg 
(relative value compared with 
control) 
364 
509 
(x1.40) 
813* 
(x2.23) 
778* 
(x2.14) 
428 
575 
(x1.34) 
693 
(x1.62) 
1045* 
(x2.44) 
* Significant when compared with untreated control group (p<0.05). 
† Group mean values not available for 6-week recovery. 
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oxyhydroxide is low and below toxic levels, even with long-term 
use at high doses [42]. Moreover, at clinically-relevant doses of  
40 mg Fe/kg/day, sucroferric oxyhydroxide was not associated with 
significant increases in liver, spleen or kidney iron values compared 
with controls after 2 years of administration in rats or after 39 
weeks of administration in dogs. Histopathological analyses 
showed that absorbed iron tended to be found in the normal sites of 
iron metabolism, such as macrophages and Kupffer cells [43], 
components of the RES. 
Efficacy of Sucroferric Oxyhydroxide in Preventing Vascular 
Calcifications in a Uraemic Rat Model 
 The preclinical studies to assess iron release properties, 
phosphate binding capacity, ADME and iron toxicity were essential 
to establish a theoretical basis for the phosphate-binding efficacy of 
sucroferric oxyhydroxide and to evaluate its potential for iron 
toxicity. An additional preclinical study was also undertaken in a rat 
model of CKD to examine the possible effects of sucroferric 
oxyhydroxide on the progression of vascular calcification, as well 
as serum phosphorus, calcium, intact parathyroid hormone (iPTH) 
and fibroblast growth factor 23 (FGF23) concentrations, compared 
with calcium carbonate [52]. 
 CKD was chemically induced in rats by the addition of adenine 
to their high-phosphorus diet. The rats were then administered 
sucroferric oxyhydroxide (at a concentration of 0.5%, 1.5% or 
5.0%), calcium carbonate (at a concentration of 3%) or no treatment 
(CKD control group). Three additional groups also received the 
high-phosphorus pre-treatment diet for 4 weeks but without 
adenine, so CKD was not induced. The non-CKD groups then 
received either no treatment (non-CKD control group), sucroferric 
oxyhydroxide 5%, or calcium carbonate 3% for 4 weeks. After 4 
weeks of treatment, blood pressure and heart rate were assessed. 
The rats were then sacrificed and blood was taken for biochemical 
analysis. Parameters measured included haematocrit and serum 
phosphorus, calcium, iPTH and FGF23, among others. Vascular 
calcifications were evaluated by histomorphometric analysis. The 
degree of calcification was scored semiquantitatively according to 
the surface of von Kossa positivity, with a score of 0 indicating no 
von Kossa positivity; 1, focal von Kossa positivity, larger than or 
not overlying a cell nucleus; 2, partially circumferential von Kossa 
positivity in the tunica medial of the vessel; and a score of 3 
indicating von Kossa positivity in the tunica media spanning the 
complete circumference of the vessel. 
 The development of CKD was associated with an increase in 
serum phosphorus, although serum calcium was not higher in rats 
with CKD after the initial 4-week adenine diet than in non-CKD 
animals. CKD rats also developed hyperparathyroidism. After 4 
weeks of phosphate binder treatment, mean serum phosphorus 
concentrations in the sucroferric oxyhydroxide 5% and calcium 
carbonate groups had normalised and were comparable with one 
another (Table 4). There were no significant differences in serum 
calcium levels between any of the treatment groups and either the 
non-CKD control or the CKD control groups (p>0.05), although it 
is notable that serum calcium levels were highest in the non-CKD 
calcium carbonate group. Sucroferric oxyhydroxide produced a 
dose-dependent reduction in serum iPTH levels after 4 weeks of 
treatment. Calcium carbonate also reduced serum iPTH levels, with 
sucroferric oxyhydroxide 5% and calcium carbonate producing 
comparable serum iPTH levels after 4 weeks. FGF23 was 
significantly reduced in the sucroferric oxyhydroxide 5% group 
compared with the calcium carbonate group and the CKD control 
group (p<0.05). No significant differences in systemic blood 
pressure or heart rate were observed between CKD rats and non-
CKD rats, or between CKD rats treated with any dose of sucroferric 
oxyhydroxide or calcium carbonate. 
 Sucroferric oxyhydroxide was found to attenuate the 
development of vascular calcifications (Fig. 4). A high proportion 
of CKD control rats (76%, n=13), rats receiving low dose (0.5%) 
sucroferric oxyhydroxide (86%, n=6), and rats receiving calcium 
carbonate (58%, n=11) developed severe vascular calcifications 
with high calcification scores (scores of 2 or 3). Just 22% of rats 
treated with sucroferric oxyhydroxide 1.5% (n=2), and the same 
proportion treated with sucroferric oxyhydroxide 5% (n=4), 
meanwhile, had high vascular calcification scores. 
 This study demonstrated the efficacy of sucroferric 
oxyhydroxide as a treatment for hyperphosphataemia. At the 5% 
Table 4. Mean serum phosphorus, calcium and iPTH concentrations in rats with or without chronic kidney disease (CKD) after 4 
weeks of treatment with sucroferric oxyhydroxide 0.5%, 1.5% or 5%, or calcium carbonate 3% [52]. Reproduced from 
Phan et al. 2013 with permission from The American Society for Pharmacology and Experimental Therapeutics. 
  N Calcium Phosphorus iPTH 
   (mg/dL ± SD) pg/mL ± SD 
Non-CKD control 8 9.60 ± 0.12 6.67 ± 0.34 105 ± 14 
Non-CKD sucroferric oxyhydroxide 5% 8 9.72 ± 0.20 5.27 ± 0.37 134 ± 50 
Non-CKD calcium carbonate 3% 8 10.00 ± 1.40 6.63 ± 0.68 102 ± 9 
CKD control 19 9.52 ± 0.48 9.02 ± 0.74 3261 ± 397 
CKD sucroferric oxyhydroxide 5% 20 9.64 ± 0.12 6.85 ± 0.28a 1138 ± 228a 
CKD sucroferric oxyhydroxide 1.5% 9 8.92 ± 0.16 7.10 ± 0.78b 2727 ± 695c 
CKD sucroferric oxyhydroxide 0.5% 9 9.56 ± 0.28 8.49 ± 1.15 4830 ± 624c 
CKD calcium carbonate 3% 19 9.56 ± 0.24 6.39 ± 0.34a 1299 ± 300a 
CKD, rats with chronic kidney disease; iPTH, intact parathyroid hormone; Non-CKD, rats without chronic kidney disease; SD, standard deviation. a, p0.001 vs CKD control;  
b, p<0.05 vs CKD control; c, p<0.05 vs CKD sucroferric oxyhydroxide 5% or calcium carbonate 3%. 
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dose, it showed comparable efficacy to calcium carbonate in 
reducing levels of serum phosphorus. Sucroferric oxyhydroxide 
was also shown to be superior to calcium carbonate at reducing the 
extent of vascular calcifications. While calcium carbonate did 
produce a reduction of vascular calcifications in CKD rats, there 
were significantly fewer animals with severe calcifications 
observed after treatment with sucroferric oxyhydroxide 5% 
(p=0.045), and sucroferric oxyhydroxide 1.5% also produced a 
significant reduction in the number of animals with severe 
calcifications compared with CKD controls (p=0.002). 
 The in vivo study described here appears to demonstrate that 
sucroferric oxyhydroxide has the potential to reduce the progression 
of vascular calcification in comparison with the calcium-based 
phosphate binder calcium carbonate. While calcium carbonate did 
reduce the progression of vascular calcification relative to untreated 
CKD controls, it is possible that calcium-based phosphate binders 
may in some way contribute to the progression of vascular 
calcifications. Further studies are required in humans to evaluate its 
potential with respect to reducing the progression of vascular 
calcifications but, as a non-calcium-based phosphate binder, 
sucroferric oxyhydroxide does constitute an attractive alternative 
for the management of hyperphosphataemia in dialysis patients. 
DISCUSSION 
 This review has provided an overview of preclinical data 
gathered in vitro and in vivo on the use of sucroferric oxyhydroxide 
as a phosphate binder for the treatment of hyperphosphataemia in 
CKD. The first study to be reviewed investigated the phosphate-
binding capacity and iron-releasing properties of sucroferric 
oxyhydroxide in vitro [37]. Sucroferric oxyhydroxide was shown to 
have potent phosphate-binding capacity and low iron release over 
the pH range present in the GI tract. New data from in vivo ADME 
studies in rats and dogs using 59Fe-labelled sucroferric 
oxyhydroxide subsequently demonstrated iron uptake to be low. 
The majority of radiolabelled iron that was absorbed was found in 
RBCs in both species. Overall, most of the radiolabelled iron was 
excreted in the faeces. This indicates both that the iron in 
sucroferric oxyhydroxide is predominantly utilised to bind 
phosphate in the GI tract, and that the small amount of iron which is 
absorbed is processed via normal metabolic pathways, with the 
majority being found in RBCs. 
 The potential toxicity of sucroferric oxyhydroxide was 
investigated in a series of seven sub-chronic, chronic and long-term 
studies conducted in rats and dogs. Data from these studies 
presented in this review show that long-term (up to 2 years) 
administration of sucroferric oxyhydroxide is associated with 
modest increases in tissue iron levels that fall well below those 
associated with iron toxicity [42]. Absorption of iron in the GI tract 
plays a key role in the maintenance of iron levels and, in the normal 
state, increasing iron stores tend to inhibit intestinal iron absorption 
[44, 56]. Despite this, excessive dietary intake or abnormally 
increased intestinal absorption can still lead to iron overload in the 
liver and other tissues [56-58]. The small increases in tissue iron 
levels observed in the rat and dog studies described here suggest that 
uptake of iron released from sucroferric oxyhydroxide proceeds via 
the normal metabolic pathways, thus limiting excessive absorption. 
The fact that most of the iron found in the liver and the spleen was in 
the cells of the RES also supports the conclusion that iron absorbed 
from sucroferric oxyhydroxide is directed to normal metabolism; in 
humans, macrophages of the spleen and Kupffer cells of the liver are 
responsible for recycling around 25 mg of iron from ageing RBCs 
per day, while hepatocytes provide an iron storage facility [43]. 
 It is also notable that the maximum increases in liver iron 
values were no more than 3.1 times greater in treated rats than in 
controls, and no more than 2.5 times greater in treated dogs than in 
controls. To put this into context, a toxicity study of a parenteral 
iron preparation in dogs found that signs of iron overload toxicity 
appear only when levels of liver iron rise to between 13 and 50 
times greater than those observed in controls [42]. 
 Based on the low iron release observed in the in vitro study, and 
the low absorption and accumulation of iron seen in the animal 
studies, it can be expected that sucroferric oxyhydroxide will 
exhibit a favourable long-term safety profile in the clinical setting. 
Indeed, Phase I and III clinical studies in CKD patients have shown 
that sucroferric oxyhydroxide is associated with minimal systemic 
 
 
Fig. (4). Percentages of rats with high vascular calcification scores (scores of 2 or 3 on a scale from 0–3, with 0 representing no von Kossa activity and 3 
representing von Kossa positivity in the tunica media spanning the complete circumference of the vessel) after 4 weeks of treatment with sucroferric 
oxyhydroxide 0.5%, 1.5% or 5%, or calcium carbonate 3% [52]. CKD, chronic kidney disease. 
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absorption and low risk of iron overload [35, 59]. In the Phase I 
study, serum phosphorus levels decreased in non-dialysis CKD 
patients and haemodialysis patients over 7 days of treatment with 
10 g/day sucroferric oxyhydroxide, while uptake of iron from a 
single 
59
Fe-labelled dose was very low: at 21 days after 
administration of the radiolabelled dose, median iron uptake was 
0.06% (range: 0.008–0.44%) in non-dialysis-dependent CKD 
patients and 0.02% (range: 0–0.04%) in haemodialysis patients 
[35]. This was approximately ten-fold lower than iron uptake in 
healthy control subjects with low iron stores, in whom the median 
iron uptake was 0.43% (range: 0.16–1.25%). In all groups, the 
increase in 
59
Fe plateaued at approximately 2 weeks after 
administration. There were also no changes in iron indices after a 
week of treatment. 
 In the Phase III study, sucroferric oxyhydroxide was found to 
be non-inferior to sevelamer carbonate at reducing serum 
phosphorus in haemodialysis and peritoneal dialysis patients after 
24 weeks of treatment, with no evidence of iron overload [59]. 
While sucroferric oxyhydroxide was associated with increases in 
ferritin and transferrin concentrations, increases in ferritin were also 
observed among patients receiving sevelamer carbonate. As 
increases in these parameters occurred early during the study and 
flattened out over time, it was concluded that no iron accumulation 
was taking place. The absorption of a small amount of iron from 
sucroferric oxyhydroxide could not be ruled out, however. 
Although over 70% of the overall study population (patients 
receiving sucroferric oxyhydroxide or sevelamer carbonate) were 
receiving concomitant intravenous iron during the study, which 
may account for some of the observed increases in iron parameters, 
increases in serum ferritin and transferrin were slightly higher 
among patients receiving sucroferric oxyhydroxide than sevelamer 
carbonate. Thus it would appear that a small amount of iron was 
being absorbed, in line with the findings of the Phase I study. In a 
long-term extension of the Phase III trial, no evidence for iron 
accumulation or overload was observed with up to 1 year of 
treatment with sucroferric oxyhydroxide [60]. 
 The preclinical uraemic rat model study discussed in this 
review showed that sucroferric oxyhydroxide may prevent the 
progression of vascular calcifications [52]. The study compared the 
effects of sucroferric oxyhydroxide and an existing calcium-based 
phosphate binder, calcium carbonate, on rats with adenine-induced 
CKD. Sucroferric oxyhydroxide reduced serum phosphorus levels 
in a dose-dependent manner, and after 4 weeks both sucroferric 
oxyhydroxide 1.5% and 5%, and calcium carbonate 3%, had 
significantly reduced serum phosphorus levels relative to untreated 
CKD controls. Although both sucroferric oxyhydroxide and 
calcium carbonate were also comparable in their effects on serum 
calcium and iPTH levels, sucroferric oxyhydroxide 5% was 
associated with a significantly reduced progression of vascular 
calcifications in comparison with calcium carbonate. 
 One possible explanation for the reduced vascular calcification 
in rats treated with sucroferric oxyhydroxide compared with 
calcium carbonate could be that the protective effect of the calcium-
based phosphate binder is limited by the absorption of calcium [52], 
which can alter the calcium balance and may lead to calcification of 
vascular smooth muscle cells [61, 62]. The observation that serum 
calcium levels were comparable between CKD rats treated with 
sucroferric oxyhydroxide and those treated with calcium carbonate 
would appear to argue against this explanation. It should be noted 
that similar observations have been reported previously by Spiegel 
et al. in a human study of patients with Stage 3–4 CKD, which 
found that increasing calcium intake from 800 to 2000 mg did not 
result in a concomitant increase in serum calcium levels [62]. As 
serum calcium concentrations are known to be tightly regulated, it 
may be argued that high calcium intake may cause calcium 
overload in the tissues without increasing the serum calcium 
concentration [62]. Indeed, this is what was found by Spiegel et al., 
who reported that the overall calcium balance (defined as oral 
calcium intake less urinary and faecal calcium output) did increase 
when the calcium intake was increased to 2000 mg, despite the lack 
of an increase in serum calcium levels. As a non-calcium based 
phosphate binder, sucroferric oxyhydroxide may help to avoid the 
increases in calcium balance that could potentially be caused by the 
uptake of calcium from calcium-based phosphate binders such as 
calcium carbonate, and which may precipitate or worsen vascular 
calcification [52, 62]. 
 Another possibility is that, rather than affecting vascular 
calcification directly, sucroferric oxyhydroxide and calcium 
carbonate affect the progression of calcification by differentially 
modulating serum levels of FGF23. Raised serum levels of FGF23 
have previously been shown to be correlated with severe vascular 
calcifications in haemodialysis patients, and it has been argued that 
FGF23 is independently associated with vascular calcification [63, 
64]. In the preclinical study described here, treatment with 
sucroferric oxyhydroxide was associated with lower levels of 
FGF23 than was treatment with calcium carbonate, even though 
serum phosphorus, calcium and iPTH levels were comparable [52]. 
It may be suggested that calcium uptake from calcium carbonate 
causes an increase in serum levels of FGF23, which then enhances 
the development of vascular calcifications. Indeed, FGF23 levels 
have been found to correlate positively with both ionised calcium 
and the calcium phosphate product (which is an independent 
predictor for coronary calcifications) in human patients with CKD 
aged over 12 years [65]. Calcium deficiency, meanwhile, has 
previously been shown to reduce FGF23 levels in rats with normal 
renal function [66]. Despite this, the evidence for a modulatory role 
of FGF23 on vascular calcifications is equivocal. A recent study 
into the association between FGF23 and arterial calcification in 
patients with CKD showed that, after adjustment for the traditional 
coronary risk factors associated with elevated FGF23, higher 
plasma FGF23 was not associated with coronary artery 
calcifications [67]. In the same study, mRNA expression of FGF23 
or its coreceptor, klotho, could not be found in either human or 
mouse smooth muscle cells, or in normal or calcified mouse aorta. 
Interestingly, the severity, but not the presence, of thoracic artery 
calcification was found to be associated with levels of FGF23, but 
this latter finding may have been an artefact of the complex data 
modelling required in this study. 
 The question of whether or not calcium-based phosphate 
binders should be used in clinical practice has become the subject 
of extensive debate. In a recent systematic review and meta-
analysis of 847 reports, including 14 randomised trials, Jamal et al. 
found that calcium-based phosphate binders are associated with an 
increased risk of all-cause mortality in people with CKD compared 
with non-calcium-based phosphate binders [68]. In the 11 
randomised trials included in this analysis that reported an outcome 
of mortality, patients who were assigned to non-calcium-based 
phosphate binders had a 22% reduction in all-cause mortality 
compared with those assigned to calcium-based phosphate binders. 
Similar reductions in mortality were observed for patients assigned 
to non-calcium-based, rather than calcium-based, phosphate binders 
in non-randomised trials and when pre-dialysis and dialysis patients 
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were considered separately. Jamal et al. also reported an increase in 
coronary artery calcification among patients treated with calcium-
based phosphate binders versus those receiving non-calcium-based 
phosphate binders. Earlier reviews of the literature have also 
reported a greater progression of vascular calcification with the use 
of calcium-based, rather than non-calcium-based, phosphate binders 
[69]. 
 The meta-analysis by Jamal et al. did not determine whether the 
increased mortality observed among patients administered calcium-
based phosphate binders was due to an increase in cardiovascular 
events [68]. Vascular calcification is known to be a risk factor for 
ischaemic heart disease in non-uremic individuals, however, and 
vascular calcifications have been directly linked to the prevalence 
of cardiovascular events [70].  
 Calcium-based phosphate binders, such as calcium carbonate, 
have been shown to affect the calcium balance [28], and have also 
been associated with hypercalcaemia [71] and vascular 
calcifications [69]. As a non-calcium-based phosphate binder, 
sucroferric oxyhydroxide may help to reduce the progression of 
vascular calcification by avoiding contributing to these processes. It 
is essential that further studies are undertaken in human subjects to 
properly assess the potential for sucroferric oxyhydroxide to slow 
the progression of vascular calcifications in the clinical setting. As 
discussed earlier in this review, further research is also needed to 
determine the mechanism(s) by which calcium-based phosphate 
binders contribute to the development of vascular calcification. 
 The high phosphate-binding capacity, minimal iron release and 
low toxicity of sucroferric oxyhydroxide observed in preclinical 
studies, along with its positive effect on the development of 
vascular calcification, recommend it as a strong candidate for the 
treatment of hyperphosphataemia in clinical practice. Indeed, Phase 
II and Phase III trials have confirmed its efficacy and safety in 
clinical practice [36, 59]. In the Phase II trial, sucroferric 
oxyhydroxide significantly reduced serum phosphorus in 
haemodialysis patients at doses of 1.0–2.5 g Fe/day with an adverse 
event rate similar to that of sevelamer hydrochloride [36]. In the 
Phase III trial, sucroferric oxyhydroxide was shown to be non-
inferior to sevelamer carbonate at reducing and maintaining serum 
phosphorus, with a substantially lower pill burden (on average, 3.1 
versus 8.1 pills per day for sucroferric oxyhydroxide- and 
sevelamer carbonate-treated patients, respectively) [59]. The 
percentage of patients that reported at least one treatment-emergent 
adverse event (TEAE) was, however, found to be slightly higher 
with sucroferric oxyhydroxide (83.2%) than with sevelamer 
carbonate (76.1%). 
 In addition to good efficacy, efficiency regardless of pH, 
minimal absorption in the digestive tract and/or deposition in the 
tissues, and minimal side effects, other attributes that could identify 
a phosphate binder as an ideal treatment include good palatability 
and a sufficiently low pill burden to help ensure adherence to 
treatment [9, 23, 24]. As mentioned above, sucroferric 
oxyhydroxide is associated with a considerably lower pill burden 
than sevelamer carbonate [59]. Consideration was also given to 
patient preferences and practicality when designing the dosage 
form. Surveys suggest that patients prefer a single dosage form to 
multiple tablets for swallowing, which may also be impractical 
when a treatment is typically administered in high doses [51]. In 
addition, avoiding excess water intake – such as might be required 
for swallowing whole tablets – is advantageous for patients with 
CKD. Disintegration of a chewable tablet is also important to 
ensure that efficacy is not lost should chewing be incomplete after 
administration. Considering these factors, sucroferric oxyhydroxide 
has been designed as a chewable tablet that disintegrates readily 
into smaller particles to allow for optimal adsorption of phosphate. 
In vitro assessments of the chewability of sucroferric oxyhydroxide 
tablets showed them to be able to withstand the high breaking 
forces required to achieve low friability, while still being 
adequately chewable [51]. 
 In conclusion, sucroferric oxyhydroxide is a new, iron-based 
phosphate binder that offers high phosphate-binding capacity over 
the physiologically-relevant pH range and minimal iron release in 
vitro [37]. In vivo studies have indicated a good long-term safety 
profile, with no iron toxicity and minimal accumulation associated 
with long-term use. An in vivo study using a uraemic rat model has 
also indicated that sucroferric oxyhydroxide may slow the 
progression of cardiovascular calcifications in rats [52], although 
this finding requires further evaluation in human trials before 
conclusions can be drawn about its clinical significance. The safety 
and efficacy of sucroferric oxyhydroxide have been confirmed in 
Phase I, II and III clinical trials, which have also demonstrated a 
low pill burden and possible improved treatment adherence in 
comparison with sevelamer carbonate [35, 36, 59]. Furthermore, the 
chewability of sucroferric oxyhydroxide [51] offers a dosage form 
which may be more amenable to patients and more practical in 
terms of administration. Sucroferric oxyhydroxide therefore 
constitutes a promising new alternative to the available phosphate 
binder treatments. 
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ADME = Absorption, distribution, metabolism and 
excretion 
CKD = Chronic kidney disease 
CKD-MBD = Chronic kidney disease mineral bone disorder 
ESRD = End-stage renal disease 
FGF23 = Fibroblast growth factor 23 
GFR = Glomerular filtration rate 
GI = Gastrointestinal 
iPTH = Intact parathyroid hormone 
K/DOQI = Kidney Disease Outcomes Quality Initiative 
NTBI = Non-transferrin-bound iron 
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PTH = Parathyroid hormone 
RBC = Red blood cell 
RES = Reticuloendothelial system 
RR = Relative risk 
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